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To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate 
(Cal/BD) cutaneous foam against non-biologic systemics in psoriasis patients for whom oral 
systemic or topical therapy is considered appropriate in seven European countries.  
Methods  
Matching-adjusted indirect comparisons of 4-week PASI-75 responses of Cal/BD foam were 
performed versus 12-week responses of methotrexate, acitretin, fumaric acid esters (FAE) and 
16-week responses of apremilast. Analyses took a payer perspective and included drug, 
physician visit and monitoring costs.   
Results  
In all countries, Cal/BD foam generated the lowest cost per responder (CPR). Against 
methotrexate, apremilast and acitretin, Cal/BD foam generated response for less than €190 in 
Italy, €195 in Portugal, €216 in Greece, £218 in the UK, €250 in Belgium, €319 in Spain, and 
€359 in the Netherlands. Relative to treatment with FAE, Cal/BD foam resulted in response for 
less than €298, €430, €382 and £262 in Belgium, the Netherlands, Spain and the UK, 
respectively. For Cal/BD foam, apremilast and FAE, total costs were driven by drug costs; for 
methotrexate and acitretin, by monitoring. 
Conclusions  
Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective 
option over the short-term in the investigated psoriasis population. 
Keywords: psoriasis; calcipotriol/betamethasone dipropionate cutaneous foam; topical therapy; 












Psoriasis is a chronic, immune-mediated inflammatory condition primarily manifesting on the 
skin and is estimated to affect 2-3% of the world’s population [1]. Plaque psoriasis symptoms 
negatively impact patient quality of life and are associated with a considerable economic 
burden [2,3]. Treatment aims to reduce the severity of skin symptoms and to improve patient 
quality of life. 
Topical therapies are usually considered the first line option in mild to moderate psoriasis 
while phototherapies or oral systemic therapies are generally offered for moderate to severe 
disease or after failure of topical therapy. Systemic therapies are often associated with greater 
costs to the healthcare system than topical treatments, driven by costs of medication and 
monitoring [3]. Individual patient characteristics and preferences determine the choice of 
treatment prescribed by physicians. 
A frequently used first-line topical psoriasis treatment is the fixed-dose combination of 
calcipotriol (Cal, 50 μg/g) and betamethasone dipropionate (BD, 0.5 mg/g). The Cal/BD 
combination formulation has a comparable safety profile and is more effective in treating 
psoriasis compared to monotherapy with either calcipotriol or betamethasone dipropionate [4-
7]. A novel cutaneous foam developed for the fixed-dose Cal/BD combination has 
demonstrated significantly improved efficacy with a comparable safety profile when 
compared to Cal/BD gel and ointment [8,9], a foam vehicle [10] and Cal or BD foams alone 
[11].  
A recent matching-adjusted indirect comparison (MAIC) [12], showed Cal/BD foam to have 
better effectiveness compared to apremilast, methotrexate and acitretin and to have 
comparable effectiveness versus fumaric acid esters (FAE) in patients eligible for either 











relatively low acquisition costs but require regular doctor visits and monitoring for adverse 
events. By comparison, treatments such as apremilast and FAE are associated with higher 
acquisition costs, and potentially less frequent monitoring in the case of apremilast. Cal/BD 
foam requires no ongoing monitoring and could be prescribed in general practice. Pharmaco-
economic data on whether Cal/BD foam offers better value for money in patients who are 
eligible for both topical and systemic therapy is essential for optimal decision making in 
restricted health care budget systems.  
The objective of this study is to compare the costs and effectiveness of Cal/BD foam with 
that of non-biologic systemic therapies in patients eligible for topical and non-biologic 
systemic treatment in seven European countries: Belgium, Greece, Italy, the Netherlands, 
Portugal, Spain and the United Kingdom. 
Materials and methods 
Responder rates 
Response was defined as a 75% reduction in the Psoriasis Area and Severity Index score 
(PASI-75). The proportion of patients responding to Cal/BD foam and oral systemic therapies 
were derived from a recently published MAIC [12]. MAIC is a methodological approach for 
indirect comparisons where no appropriate common comparator is available and individual 
patient data (IPD) are available for at least one intervention. Here, IPD from 4 Cal/BD foam 
randomised controlled trials (RCTs) were matched to average study population characteristics 
from published studies of non-biologic systemic therapies.  
A separate MAIC was available for Cal/BD foam versus each non-biologic systemic therapy. 
In each comparison, the IPD from pooled Cal/BD foam trials were re-weighted such that the 











each comparator study (see Supplementary Table 1). As a result, the absolute responder rate 
of Cal/BD foam is unique for each matched comparison. The PASI-75 endpoint of the 
Cal/BD foam trials at week 4 were compared to the PASI-75 endpoints of the comparator 
trials, which were measured at week 12 for methotrexate, acitretin and FAE, and week 16 for 
apremilast. Results from a sensitivity analysis comparing the week 12 outcomes for Cal/BD 
foam (only reported in the PSO-ABLE study) [8] to the week 12 or week 16 outcomes for the 
non-biologic systemic therapies were also available [12].  
[Table 1 near here] 
Table 1 presents the MAIC results from Bewley et al., which fed into the present cost per 
responder analysis. These results indicate that, among patients considered for either topical or 
non-biologic systemic treatment, Cal/BD foam for either 4 weeks or 12 weeks is expected to 
generate significantly more PASI-75 responders than 12 weeks of treatment with acitretin or 
methotrexate or 16 weeks of treatment with apremilast. Compared to 12 weeks of therapy 
with FAE, the absolute responder rate for Cal/BD foam is lower over 4 weeks (42.4% vs 
47.0%) and higher over 12 weeks of treatment (58.5% vs 47.0%), though the differences are 
not statistically significant at either time point. No comparison could be made with 
ciclosporin due to a lack of data [12].  
Costs and health care resource use 
The analysis took a payer perspective for each of the European countries and considered both 
drug and monitoring costs based on local databases and national guidelines. Not all non-
biologic systemic therapies are available or used in all countries. For example, neither 











Methotrexate administered via injection is rarely used in the UK, Greece, Belgium and the 
Netherlands and was therefore not evaluated in these countries. 
Drug costs were calculated by combining the total dose received during treatment with local 
drug costs obtained from published sources (see Supplementary Table 2). For Belgium and 
the Netherlands, the pharmacy selling price was used. In Portugal and Spain, drug costs were 
based on their wholesale purchase price and in Greece they were based on the reimbursed 
prices. In Italy, the ex-factory wholesale purchase price was used with mandatory discounts (-
5%; -5%) included. Finally, list prices in the UK were taken from the National Health Service 
drug tariff.  
The Cal/BD foam dose was estimated as a weighted average of 4-week consumption across 
the included Cal/BD foam RCTs [8-11]. Non-biologic systemic therapy doses were 
determined according to European Medicines Agency label or the trial included in the 
analysis and calculated for treatment duration.  
The consumption of methotrexate could not be derived from the observational study 
synthesised in the MAIC [13], so was calculated based on the label posology [14] and a 
titration period validated by clinical experts. Patients were assumed to start on 7.5 mg of 
methotrexate per week and escalate to 10 mg in weeks 2 and 3, to 15 mg in weeks 4 to 6, to 
20 mg in weeks 7 to 10 and to 25 mg in weeks 11 and 12. This amounts to an average weekly 
dose of 16.9 mg for the first 12 weeks. The dose of acitretin is determined by patient weight 
and was derived from Chiricozzi et al. [15], the observational study synthesised in the MAIC. 
The mean dosage in this study was 25.01 mg (SD±6.79) corresponding to a mean of 0.31 
mg/kg. Multiplied by the mean patient weight from the PSO-ABLE study (87 kg), the mean 











titration. Dimethyl fumarate was given at a daily dose of 240 mg 3 times daily after a 9-week 
titration schedule. 
The type and frequency of general practitioner (GP) visits, specialist dermatologist visits and 
monitoring tests for each therapy were based on published guidance, where available, and 
clinical expert opinion (see Supplementary Table 3). Baseline tests were also included as 
these differed across treatments. Unit costs of health care visits and laboratory tests were 
combined with country-specific estimates of resource use to estimate the total cost of 
physician visits and monitoring (see Supplementary Table 4). Liver ultrasound and biopsies 
for methotrexate were excluded as a very small percentage of patients are assumed to require 
this and such testing falls outside the first 12 weeks of therapy. All health care resource use 
and cost inputs were validated by local clinical experts. 
Table 2 presents the total and disaggregated costs for the treatment period by country. 
[Table 2 near here] 
Scenario analysis 
The primary analysis used 4-week costs and outcomes for Cal/BD foam and compared them 
to the 12-or 16-week costs and outcomes for non-biologic systemic therapies. Differences in 
time points reflect the use of each therapy within its label and correspond to the primary 
endpoints in the included trials.  
Two scenarios were tested to increase comparability between topical and non-biological 
systemic treatment duration. In the first scenario, the results of the MAICs using the PASI-75 
responder rate from week 12 for Cal/BD foam from the PSO-ABLE [8] study were combined 











endpoint for systemic therapies. In the second, resource use and costs for all comparators 
were amended to reflect only the first four weeks of treatment, including early follow-up 
visits and drug titration where applicable. Responder rates were unchanged from the main 
analysis. That is, costs reflect the first 4 weeks of treatment, but responder rates reflect 12 to 
16 weeks of non-biologic systemic treatment and 4 weeks of Cal/BD foam. For inputs to 
these scenario analyses, see Supplementary Table 5. 
Results 
Among patients analysed in this study, Cal/BD foam is associated with a lower cost per 
PASI-75 responder than the non-biologic systemic therapies included in the analysis (Fig. 1). 
Note that the absolute PASI-75 response rate of Cal/BD foam depends on the matched 
comparison; therefore, its cost per response differs depending on the comparator.  
Methotrexate has the lowest drug costs but is among the treatments associated with the 
highest monitoring costs. The drug costs for acitretin are higher than Cal/BD foam in the UK, 
Belgium, the Netherlands and Portugal and lower in Spain, Greece and Italy; however, 
physician visit and monitoring costs are higher across all countries. Monitoring costs for FAE 
are higher than for acitretin and lower than for methotrexate (except in Italy), but FAE has a 
considerably higher drug cost. Apremilast is the systemic with the lowest monitoring costs, 
but the drug itself costs more than twice as much as any other therapy over a 12- to 16-week 
period. Cal/BD foam has the lowest total costs, because it requires no laboratory testing at 
baseline and few, if any, follow-up visits. Even if all Cal/BD foam treated patients are 
assumed to have two specialist visits in the first 4 weeks of treatment, it remains the option 











In comparison with methotrexate, apremilast and acitretin, the cost per response for Cal/BD 
foam ranged from €216 (€109.54/0.508) in Greece to €359 (€182.16/0.508) in the 
Netherlands. The cost per PASI-75 response of oral methotrexate, on the other hand, ranged 
from €480 (€160.83/0.335) in Italy to £1,865 (£624.90/0.335) in the UK. In Italy, Portugal 
and Spain, where methotrexate is available in injection form, the costs per response were 
€675, €1,136 and €1,241, respectively. For acitretin, the cost per response was as low as €560 
(€177.55/0.317) in Greece and up to €1,735 (€549.84/0.317) in the Netherlands. Apremilast 
was universally associated with the highest cost per responder, ranging from approximately 
€9,500 (€2,052.52/0.216) in Greece to more than €15,600 (€3,387.53/0.216) in Spain. 
Cal/BD foam had a higher cost per response when compared with FAE (from €228 
[€96.76/0.424] in Italy to €382 [€162.17/0.424] in Spain) than when compared to other oral 
systemic treatments due to the lower expected responder rate generated in the MAIC. 
However, the cost to generate a PASI-75 responder is substantially greater for FAE than 
Cal/BD foam, ranging from around €1,800 (€852.46/0.470) in Italy to nearly €2,600 
(€1,216.75/0.470) in the Netherlands. 
[Table 3 near here] 
In the first scenario analysis, presented in Table 3, where Cal/BD foam was assumed to be 
used for 12 weeks instead of four, both total costs and the proportions of responders 
increased, though at different rates. The costs increased proportionally more than the 
responder rate, resulting in an increase to the cost per PASI-75 response for Cal/BD foam; 
however, it remained substantially lower than all comparator non-biologic systemic therapies 
in all markets.  
In the second scenario, the total costs for non-biologic systemic therapies decreased 











four weeks of treatment. In this conservative scenario, Cal/BD foam treatment was less costly 
than all comparators and remained the treatment with the lowest cost per PASI-75 response in 
all markets. Neither scenario showed the conclusions of the main analysis to be sensitive to 
reasonable variation in cost or efficacy assumptions. 
Discussion 
This study compared the relative effectiveness and costs of treatment with Cal/BD foam 
versus non-biologic systemic therapies in seven European countries. The cost per responder 
analysis applied country-specific costs and resource use and combined it with PASI-75 
response rates from a recently published MAIC analysis, which evaluated Cal/BD foam and 
non-biologic systemic therapies in a population of patients eligible for topical and non-
biologic systemic therapies [12].  
There is a clear distinction between patients with mild and severe psoriasis in terms of both 
symptoms and treatment received: topical therapy is the preferred treatment for mild patients, 
while the latter require systemic treatment. Additionally, there is an ill-defined group of 
psoriasis patients that falls in the middle of this spectrum, which is the target population for 
our study. This patient population is clinically heterogenous, and there is no consensus on 
their treatment.  Determining the best value treatment for these patients, whilst tailoring care 
to individual patient needs and preferences, may lead to the consideration of a number of 
treatments and modalities. This cost per responder analysis demonstrated that Cal/BD foam is 
consistently associated with better or comparable response rates at a lower total cost than 
methotrexate, acitretin, apremilast and FAE.  
Older non-biologic systemic therapies (methotrexate, acitretin and FAE) are associated with 











treatment monitoring [16-18]. Psoriasis patients are a group with significant comorbidities 
[19] and the risk of hepatotoxicity with methotrexate therapy is increased among patients 
with obesity, diabetes or pre-existing liver conditions [20]. Topical treatment alternatives 
such as Cal/BD foam minimise the risk of additional comorbidities associated with 
conventional systemic therapies that have costs that were not accounted for in this analysis. 
Of course, the presence of a co-morbidity such as psoriatic arthritis would favour systemic 
therapy over topical treatments regardless of the severity of plaque psoriasis.  Hence, the 
optimal type of treatment (e.g. topical, phototherapy or systemic treatment) will vary by 
individual, and the prescribing physician will need to consider disease activity, co-
morbidities and patient preference, among others. 
Frequent monitoring visits for systemic therapies are not only inconvenient but can cost the 
patient a great deal in terms of travel and time away from work or family. The payer 
perspective adopted in this analysis does not capture these costs and does not reflect 
differences in access observed in the countries included. For example, in an archipelagic 
country like Greece, patients living on small islands may not have access to specialist or 
laboratory care and might need to travel to seek such services. 
Furthermore, while some studies assessing patients’ compliance report that relative to 
systemic treatments, topical therapies are associated lower treatment adherence [21-23], 
others report the opposite [6,24]. Both patient- and drug-related factors contribute to non-
adherence to topical therapy, including but not limited to, side-effects, time for application 
and “messiness” of the drug [6]. Cal/BD foam is greatly preferred to topical ointments and 
creams due to its ease of application and lack of mess [25].  
Guidelines for psoriasis tend to group ill-defined moderate psoriasis patients with the more 











phototherapy, biologics, and systemics [26]. However, patients may have contra-indications 
to systemic agents or may be reluctant to initiate systemic therapy. Given the enhanced 
efficacy of the novel Cal/BD foam formulation at a relatively lower cost, it may be beneficial 
for physicians to consider Cal/BD foam prior to starting a systemic therapy in patients who 
are eligible for both topical and systemic therapy. For this category of psoriasis patients, 
optimal use of an effective topical treatment can be of clinical value, reducing or delaying 
escalation to potentially more aggressive treatments, such as systemic therapy [27]. Finally, 
our study findings support that Cal/BD foam may represent a cost-effective solution ensuring 
pharmacoeconomic value in addition to clinical benefit. 
Strengths and Limitations 
The study and its results should be interpreted in the context of certain strengths and 
limitations. This is the first analysis to compare the costs and effectiveness of Cal/BD foam to 
non-biologic systemic therapies in a population of patients who could be considered for 
either. This was enabled by a published MAIC analysis, which took advantage of patient-
level data to account for differences in populations between Cal/BD foam clinical trials and 
studies of non-biologic systemic therapies, thus enabling comparisons not yet made in head-
to-head trials or in network meta-analyses [12]. Though data were available for methotrexate 
[13], acitretin [15], apremilast [28] and FAE [29], no studies provided sufficient data about 
ciclosporin and therefore it could not be included in the cost per responder comparison 
presented here. The studies in the MAIC were not all RCTs, thus the results could be 
confounded by unobserved differences between patient populations. Indeed, MAIC methods 
can only account for known confounders or differences in patient populations that are 












The main limitation of this study is the comparison across different time points, though these 
are in line with the label usage for each treatment. Cal/BD foam is recommended for a 4-
week flare treatment, while systemic therapies are intended for longer-term treatment and 
they take a longer time (12-16 weeks) to achieve maximal effect. Though the main analysis 
compared the 4-week costs and outcomes of Cal/BD foam to 12- and 16-week costs and 
outcomes of non-biologic systemic therapies, the results were not sensitive to variation in the 
duration of the treatment period. Cal/BD foam was still associated with the lowest cost per 
PASI-75 response when the treatment period was extended to 12 weeks, though this 
technically falls outside of its label usage. The analysis has focused on short-term 
effectiveness as data on the use of Cal/BD foam over the long-term, that is beyond 12 weeks, 
is limited. 
Cal/BD cost was also the lowest in a conservative scenario where the costs of non-biologic 
systemic therapies were restricted to the first 4 weeks, but the effects were held at rates 
observed after the full 12- or 16-week period. The main properties of Cal/BD foam, namely 
that it could be effective in eligible patients, requires no monitoring and can be prescribed in 
primary care, outweigh the high monitoring and follow-up costs for methotrexate and 
acitretin and the high acquisition costs for apremilast and FAE.  
Though there have been many advances in psoriasis treatment made over the last few 
decades, many systemic therapies are costly and leave some needs unmet. This cost per 
responder analysis demonstrated that Cal/BD foam, used over 4-12 weeks, can generate more 
PASI-75 responders than apremilast, acitretin and methotrexate and a comparable proportion 
of responders to FAE at a lower total cost in patients eligible for either topical or systemic 
treatment. These results indicate a potential economic benefit of Cal/BD foam and supports 
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Table 1. Proportion of PASI-75 responders with Cal/BD foam vs non-biologic systemic 
therapies 







Fumaric acid esters 
(12 weeks) 
Systemic therapy 
PASI-75 33.5% 21.6% 31.7% 47.0% 
(95% CI)  (27.2, 39.8) (15.8, 28.9) (17.5, 46.0) (37.9, 56.1) 
Cal/BD foam  
(4 weeks) 
PASI-75 50.8% 51.1% 50.9% 42.4% 
(95% CI) (50.3, 51.3) (50.5, 51.7) (50.1, 51.6) (35.0, 50.2) 
p value <0.001 <0.001 0.009 0.451 
Cal/BD foam  
(12 weeks) 
PASI-75 59.8% 60.4% 77.5% 58.5% 
(95% CI) (52.2, 66.8) (50.5, 69.5) (66.8, 85.6) (47.9, 68.4) 
p value <0.001 <0.001 <0.001 0.11 
Source: Bewley et al. 2018 [12] Note: p values are for Cal/BD foam vs systemic therapy. Abbreviations: 












Table 2. Drug consumption and healthcare costs in seven European countries 


















117.1 g 202.5 mg 202.5 mg 6570 mg 2268 mg 34020 mg 
Belgium costs  
Drug (PSP) €93.82 €21.79 N/A €3,156.01 €175.31 €806.28 
Physician €32.58 €233.88 N/A €65.16 €65.16 €90.59 
Monitoring €0.00 €103.60 N/A €0.00 €41.33 €41.57 
Total €126.40 €359.26 N/A €3,221.17 €281.79 €938.44 
Greece costs  
Drug (reimbursed 
price) 
€89.54 €5.52 N/A €2,012.89 €64.83 N/A 
Physician €20.00 €40.00 N/A €20.00 €20.00 N/A 
Monitoring €0.00 €180.42 N/A €19.63 €92.73 N/A 
Total €109.54 €225.94 N/A €2,052.52 €177.56 N/A 
Italy costs  
Drug (ex-factory 
price) 
€69.56 €9.78 €74.93 €3,018.86 €57.74 €670.91 
Physician €27.20 €81.60 €81.60 €68.00 €81.60 €81.60 
Monitoring €0.00 €69.45 €69.45 €78.05 €72.85 €99.95 
Total €96.76 €160.83 €225.98 €3,164.91 €212.19 €852.46 
Netherlands 
costs 
Drug (PSP) €91.16 €13.45 N/A €3,027.95 €133.06 €791.13 
Physician €91.00 €364.00 N/A €182.00 €364.00 €364.00 
Monitoring €0.00 €113.66 N/A €38.08 €52.78 €61.63 
Total €182.16 €491.11 N/A €3,248.03 €549.84 €1,216.75 
Portugal costs 
Drug (WPP) €65.09 €4.70 €198.50 N/A €79.12 N/A 
Physician €34.10 €127.10 €127.10 N/A €96.10 N/A 
Monitoring €0.00 €54.83 €54.83 N/A €38.02 N/A 
Total €99.19 €186.63 €380.43 N/A €213.24 N/A 
Spain costs  
Drug (WPP) €69.85 €4.12 €120.20 €3,265.36 €54.43 €637.35 
Physician €92.32 €124.80 €124.80 €92.32 €92.32 €129.92 
Monitoring €0.00 €170.64 €170.64 €29.85 €53.38 €64.56 
Total €162.17 €299.56 €415.64 €3,387.53 €200.13 €831.83 
UK costs  
Drug (drug tariff 
price) 
£77.44 £9.14 N/A £2,190.18 £86.74 £667.80 
Physician £33.50 £502.70 N/A £301.62 £201.08 £301.62 
Monitoring £0.00 £113.06 N/A £60.19 £87.85 £88.49 
Total £110.94 £624.90 N/A £2,551.99 £375.67 £1,057.91 
Abbreviations: Cal/BD, calcipotriol and betamethasone dipropionate; MTX, methotrexate; N/A, Not 
applicable; PSP, pharmacy selling price; WPP, wholesale purchase price 
Note: N/A indicates where the drug was not included in the analysis for a given country because it is either not 











Table 3. Cost per PASI-75 responder for Cal/BD foam compared to non-biologic systemic 
therapies when treatment duration is varied in alternative scenarios 1 and 2  



















SA1 €371 €1,072 N/A €368 €14,913 €286 €889 €379 €1,997 
SA2 €249 €697 N/A €247 €3,771 €248 €370 €298 €451 
Greece 
SA1 €336 €674 N/A €332 €9,502 €259 €560 N/A N/A 
SA2 €216 €546 N/A €214 €2,482 €215 €424 N/A N/A 
Italy 
SA1 €280 €480 €675 €278 €14,652 €216 €669 €287 €1,814 
SA2 €190 €272 €313 €189 €3,880 €190 €347 €228 €452 
Netherlands 
SA1 €460 €1,466 N/A €455 €15,037 €355 €1,735 €470 €2,589 
SA2 €359 €1,127 N/A €356 €4,001 €358 €1,121 €430 €689 
Portugal 
SA1 €277 €557 €1,136 N/A N/A €214 €673 N/A N/A 
SA2 €195 €417 €539 N/A N/A €195 €376 N/A N/A 
Spain 
SA1 € 390 € 894 € 1,241 € 386 € 15,683 € 301 € 631 € 399 € 1,770 
SA2 € 319 € 754 € 827 € 317 € 4,144 € 319 € 330 € 382 € 408 
UK 
SA1 £317 £1,865 N/A £314 £11,815 £245 £1,185 £325 £2,251 
SA2 £218 £1,184 N/A £217 £3,661 £218 £615 £262 £824 
Abbreviations: Cal/BD, calcipotriol and betamethasone dipropionate; SA, scenario analysis; MTX, 
methotrexate; N/A, Not applicable 
Note: SA1 used 12-week costs and effects for Cal/BD foam; SA2 used 4-week costs and 12- or 16-week effects 














Figure 1. Cost per PASI-75 responder for 4-week Cal/BD foam compared to methotrexate 
(12 weeks), apremilast (16 weeks), acitretin and fumaric acid esters (12 weeks) in the seven 
European countries. 
a. Belgium 
b. Greece  
c. Italy 
d. The Netherlands 
e. Portugal 
f. Spain 
g. United Kingdom 
NOTES: Apremilast cost-per-responder bars exceed scale, value is indicated on top of bar. 
Analyses carried out versus comparators recommended for use in each country, as reflected 
in graphic. Cost-per-responder for Cal/BD foam varies due to differences in the individual 
analyses carried out per pairwise comparison. Acitretin was identified as a comparator at the 
time of the analysis for Greece (b) but is now temporarily not available: the results are still 
displayed for completeness. Abbreviations: Cal/BD, calcipotriol and betamethasone 
dipropionate; FAE, fumaric acid esters; MTX, methotrexate; NA, comparison not applicable 
as comparator not recommended for use in country. 
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